{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T16:46:52Z","timestamp":1790700412875,"version":"4.1.0"},"reference-count":21,"publisher":"Bioscientifica","issue":"1","license":[{"start":{"date-parts":[[2026,6,15]],"date-time":"2026-06-15T00:00:00Z","timestamp":1781481600000},"content-version":"vor","delay-in-days":165,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["journals.bioscientifica.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2026,1,1]]},"abstract":"<jats:sec>\n                    <jats:title>Graphical abstract<\/jats:title>\n                    <jats:p\/>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Abstract<\/jats:title>\n                    <jats:sec>\n                      <jats:title>Background<\/jats:title>\n                      <jats:p>Ipilimumab, a CTLA-4-targeting monoclonal antibody, enhances T-cell activation and improves outcomes in various malignancies. However, it is associated with immune-related adverse events (IRAEs), including hypophysitis \u2013 a rare but potentially life-threatening condition. This review characterizes the clinical features, diagnostic approaches, and therapeutic strategies for ipilimumab-induced hypophysitis and explores its underlying pathophysiology through a case report and literature synthesis.<\/jats:p>\n                    <\/jats:sec>\n                    <jats:sec>\n                      <jats:title>Methodology<\/jats:title>\n                      <jats:p>We conducted a systematic review of published cases of ipilimumab-induced hypophysitis, extracting data on demographics, comorbidities, cancer types, treatment regimens, imaging findings, endocrine dysfunctions, and therapeutic outcomes. In addition, we present a detailed case report of a 60-year-old male with renal cell carcinoma who developed hypophysitis following ipilimumab\u2013nivolumab combination immunotherapy.<\/jats:p>\n                    <\/jats:sec>\n                    <jats:sec>\n                      <jats:title>Results<\/jats:title>\n                      <jats:p>The literature review included 92 patients (mean age 57; 68% male), most commonly treated for melanoma. MRI revealed pituitary abnormalities in 46 patients. The most frequent symptoms were headache and fatigue, with panhypopituitarism and secondary adrenal insufficiency being the most common endocrine manifestations. Glucocorticoids were administered in 86 patients, and 62 required hormone replacement. Only 15\/92 patients had full pituitary function recovery. Our case report mirrored these findings, with symptom onset after the third immunotherapy cycle and partial hormonal recovery following steroids.<\/jats:p>\n                    <\/jats:sec>\n                    <jats:sec>\n                      <jats:title>Conclusions<\/jats:title>\n                      <jats:p>Ipilimumab-induced hypophysitis is a significant IRAE with a variable clinical course and often irreversible endocrine dysfunction. Early recognition and management with glucocorticoids are critical, although long-term hormone replacement is frequently required. The autoimmune pathogenesis, linked to CTLA-4 expression in pituitary cells, underscores the need for further research into predictive markers and preventive strategies.<\/jats:p>\n                    <\/jats:sec>\n                  <\/jats:sec>","DOI":"10.1530\/ec-25-0697","type":"journal-article","created":{"date-parts":[[2026,1,5]],"date-time":"2026-01-05T10:37:55Z","timestamp":1767609475000},"update-policy":"https:\/\/doi.org\/10.1530\/crossmarkpolicy-10","source":"Crossref","is-referenced-by-count":4,"title":["A systematic review of ipilimumab-induced hypophysitis"],"prefix":"10.1530","volume":"15","author":[{"ORCID":"https:\/\/orcid.org\/0009-0003-7192-9650","authenticated-orcid":true,"given":"S","family":"Kim","sequence":"first","affiliation":[{"name":"1"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0007-6708-5917","authenticated-orcid":true,"given":"S N Y","family":"Teerupati","sequence":"additional","affiliation":[{"name":"2"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6179-2177","authenticated-orcid":true,"given":"J P","family":"Rissardo","sequence":"additional","affiliation":[{"name":"3"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0004-3697-1404","authenticated-orcid":true,"given":"P","family":"Patel","sequence":"additional","affiliation":[{"name":"1"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2389-4065","authenticated-orcid":true,"given":"E","family":"Lai","sequence":"additional","affiliation":[{"name":"1"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0005-6104-6904","authenticated-orcid":true,"given":"V V","family":"Byroju","sequence":"additional","affiliation":[{"name":"3"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8024-2354","authenticated-orcid":true,"given":"A L F","family":"Caprara","sequence":"additional","affiliation":[{"name":"3"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"416","published-online":{"date-parts":[[2026,1,5]]},"reference":[{"key":"2026070713565343300_bib1","doi-asserted-by":"crossref","first-page":"625","DOI":"10.2217\/fon-2016-0385","article-title":"Ipilimumab: from preclinical development to future clinical perspectives in melanoma","volume":"13","author":"Letendre","year":"2017","journal-title":"Future Oncol"},{"key":"2026070713565343300_bib2","doi-asserted-by":"crossref","first-page":"947","DOI":"10.1080\/14712598.2018.1513485","article-title":"Ipilimumab in combination with nivolumab for the treatment of renal cell carcinoma","volume":"18","author":"Gao","year":"2018","journal-title":"Expert Opin Biol Ther"},{"key":"2026070713565343300_bib3","doi-asserted-by":"crossref","first-page":"426","DOI":"10.1016\/j.jtho.2019.10.004","article-title":"Nivolumab monotherapy and nivolumab plus ipilimumab in recurrent small cell lung cancer: results from the checkmate 032 randomized cohort","volume":"15","author":"Ready","year":"2020","journal-title":"J Thorac Oncol"},{"key":"2026070713565343300_bib4","doi-asserted-by":"crossref","first-page":"1159","DOI":"10.1007\/s40618-015-0301-z","article-title":"Ipilimumab-induced hypophysitis: review of the literature","volume":"38","author":"Araujo","year":"2015","journal-title":"J Endocrinol Investig"},{"key":"2026070713565343300_bib5","doi-asserted-by":"crossref","first-page":"206","DOI":"10.1080\/00325481.2019.1709344","article-title":"Immune checkpoint inhibitors and endocrine side effects, a narrative review","volume":"132","author":"Agrawal","year":"2020","journal-title":"Postgrad Med J"},{"key":"2026070713565343300_bib6","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1016\/j.ctrv.2017.06.002","article-title":"Endocrine-related adverse events associated with immune checkpoint blockade and expert insights on their management","volume":"58","author":"Sznol","year":"2017","journal-title":"Cancer Treat Rev"},{"key":"2026070713565343300_bib7","doi-asserted-by":"crossref","first-page":"939","DOI":"10.1136\/jim-2021-002099","article-title":"Immune checkpoint inhibitor-induced hypophysitis: lessons learnt from a large cancer cohort","volume":"70","author":"Kotwal","year":"2022","journal-title":"J Investig Med"},{"key":"2026070713565343300_bib8","doi-asserted-by":"crossref","first-page":"804","DOI":"10.1634\/theoncologist.2015-0509","article-title":"Immune checkpoint inhibitors: review and management of endocrine adverse events","volume":"21","author":"Gonz\u00e1lez-Rodr\u00edguez","year":"2016","journal-title":"Oncologist"},{"key":"2026070713565343300_bib9","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1055\/a-0843-3366","article-title":"A systematic review and meta-analysis of endocrine-related adverse events associated with immune checkpoint inhibitors","volume":"51","author":"de Filette","year":"2019","journal-title":"Horm Metab Res"},{"key":"2026070713565343300_bib10","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1272\/jnms.84.201","article-title":"Review on recent topics in hypophysitis","volume":"84","author":"Sugihara","year":"2017","journal-title":"J Nippon Med Sch"},{"key":"2026070713565343300_bib11","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1038\/nrendo.2016.205","article-title":"Cancer immunotherapy \u2013 immune checkpoint blockade and associated endocrinopathies","volume":"13","author":"Byun","year":"2017","journal-title":"Nat Rev Endocrinol"},{"key":"2026070713565343300_bib12","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1111\/cen.13063","article-title":"Immune checkpoint inhibitor-related hypophysitis and endocrine dysfunction: clinical review","volume":"85","author":"Joshi","year":"2016","journal-title":"Clin Endocrinol"},{"key":"2026070713565343300_bib13","doi-asserted-by":"crossref","DOI":"10.1016\/j.beem.2019.101370","article-title":"New insight in endocrine-related adverse events associated to immune checkpoint blockade","volume":"34","author":"Elia","year":"2020","journal-title":"Best Pract Res Clin Endocrinol Metab"},{"key":"2026070713565343300_bib14","doi-asserted-by":"crossref","first-page":"281","DOI":"10.6004\/jnccn.2022.7098","article-title":"Hypophysitis and secondary adrenal insufficiency from immune checkpoint inhibitors: diagnostic challenges and link with survival","volume":"21","author":"Johnson","year":"2023","journal-title":"J Natl Compr Canc Netw"},{"key":"2026070713565343300_bib15","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1001\/jamaoncol.2017.3064","article-title":"Incidence of endocrine dysfunction following the use of different immune checkpoint inhibitor regimens: a systematic review and meta-analysis","volume":"4","author":"Barroso-Sousa","year":"2018","journal-title":"JAMA Oncol"},{"key":"2026070713565343300_bib16","doi-asserted-by":"crossref","first-page":"1132","DOI":"10.1210\/clinem\/dgad670","article-title":"Risk and incidence of endocrine immune-related adverse effects under checkpoint inhibitor mono- or combination therapy in solid tumors: a meta-analysis of randomized controlled trials","volume":"109","author":"Vardarli","year":"2024","journal-title":"J Clin Endocrinol Metab"},{"key":"2026070713565343300_bib17","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1530\/EJE-19-0238","article-title":"Hypophysitis secondary to nivolumab and pembrolizumab is a clinical entity distinct from ipilimumab-associated hypophysitis","volume":"181","author":"Faje","year":"2019","journal-title":"Eur J Endocrinol"},{"key":"2026070713565343300_bib18","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.3008002","article-title":"Pituitary expression of CTLA-4 mediates hypophysitis secondary to administration of CTLA-4 blocking antibody","volume":"6","author":"Iwama","year":"2014","journal-title":"Sci Transl Med"},{"key":"2026070713565343300_bib19","doi-asserted-by":"crossref","first-page":"1066","DOI":"10.1111\/imj.12819","article-title":"Ipilimumab-induced hypophysitis in melanoma patients: an Australian case series","volume":"45","author":"Lam","year":"2015","journal-title":"Intern Med J"},{"key":"2026070713565343300_bib20","doi-asserted-by":"crossref","first-page":"749","DOI":"10.1158\/1078-0432.CCR-14-2353","article-title":"Systemic high-dose corticosteroid treatment does not improve the outcome of ipilimumab-related hypophysitis: a retrospective cohort study","volume":"21","author":"Min","year":"2015","journal-title":"Clin Cancer Res"},{"key":"2026070713565343300_bib21","doi-asserted-by":"crossref","first-page":"389","DOI":"10.1038\/s41574-021-00484-3","article-title":"Endocrine toxicities of immune checkpoint inhibitors","volume":"17","author":"Wright","year":"2021","journal-title":"Nat Rev Endocrinol"}],"container-title":["Endocrine Connections"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/ec.bioscientifica.com\/view\/journals\/ec\/15\/1\/EC-25-0697.xml","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/ec.bioscientifica.com\/downloadpdf\/journals\/ec\/15\/1\/EC-25-0697.xml","content-type":"text\/html","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/journals.bioscientifica.com\/ec\/article-pdf\/doi\/10.1530\/EC-25-0697\/504746\/ec-25-0697.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/journals.bioscientifica.com\/ec\/article-pdf\/doi\/10.1530\/EC-25-0697\/504746\/ec-25-0697.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,7]],"date-time":"2026-07-07T17:57:56Z","timestamp":1783447076000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.bioscientifica.com\/ec\/article\/15\/1\/e250697\/75458\/A-systematic-review-of-ipilimumab-induced"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1,1]]},"references-count":21,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2026,1,1]]}},"URL":"https:\/\/doi.org\/10.1530\/ec-25-0697","relation":{},"ISSN":["2049-3614"],"issn-type":[{"value":"2049-3614","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,1,1]]},"article-number":"e250697"}}